Soleno Therapeutics (SLNO) and The Competition Financial Review
Soleno Therapeutics (NASDAQ: SLNO) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare Soleno Therapeutics to related companies based on the strength of its analyst recommendations, valuation, earnings, dividends, profitability, institutional ownership and risk.
This is a summary of recent ratings and recommmendations for Soleno Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Soleno Therapeutics Competitors||218||1266||2745||97||2.63|
Soleno Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 370.59%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.90%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Soleno Therapeutics is more favorable than its competitors.
Valuation & Earnings
This table compares Soleno Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Soleno Therapeutics||$1.45 million||-$12.06 million||-1.06|
|Soleno Therapeutics Competitors||$975.11 million||$120.37 million||258.47|
Soleno Therapeutics’ competitors have higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Soleno Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Soleno Therapeutics Competitors||-423.38%||-43.36%||-12.43%|
Volatility & Risk
Soleno Therapeutics has a beta of 5.99, suggesting that its share price is 499% more volatile than the S&P 500. Comparatively, Soleno Therapeutics’ competitors have a beta of 0.95, suggesting that their average share price is 5% less volatile than the S&P 500.
Insider and Institutional Ownership
65.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 69.8% of Soleno Therapeutics shares are owned by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Soleno Therapeutics competitors beat Soleno Therapeutics on 7 of the 12 factors compared.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.